R

Ultragenyx Pharmaceutical
D

RARE

35.680
USD
0.16
(0.45%)
مغلق
حجم التداول
13,594
الربح لكل سهم
-5
العائد الربحي
-
P/E
-6
حجم السوق
3,373,259,809
أصول ذات صلة
B
BLUE
0.00500
(0.10%)
4.99000 USD
C
CRSP
-0.760
(-2.02%)
36.850 USD
E
EDIT
-0.07000
(-4.32%)
1.55000 USD
N
NTLA
-0.30500
(-3.22%)
9.17000 USD
S
SGMO
-0.02030
(-4.11%)
0.47370 USD
V
VYGR
-0.05500
(-1.85%)
2.91500 USD
المزيد
الأخبار المقالات

العنوان: Ultragenyx Pharmaceutical

القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.